Innovative Bedside Test Achieves Over 90% Accuracy in Sepsis Prediction
New portable blood test leveraging AI achieves over 90% accuracy in early sepsis detection, enabling faster treatment and improved patient outcomes.
Researchers from the University of British Columbia have developed a groundbreaking blood test and portable device that significantly accelerates the detection of sepsis, a life-threatening response to infection. Published in Nature Communications, this new test demonstrates an accuracy rate exceeding 90% in identifying patients at high risk of developing sepsis, marking a major advance in critical care diagnostics.
Sepsis accounts for approximately 20% of all deaths worldwide, underscoring the urgency for rapid detection methods. Traditionally, diagnosing sepsis can take up to 18 hours, often requiring specialized laboratory facilities, which delays treatment and increases mortality risk. The new approach utilizes machine learning algorithms analyzing blood samples to predict sepsis before clinical symptoms fully manifest.
In a study involving over 3,000 hospital patients with suspected sepsis, researchers identified a six-gene expression signature, called "Sepset," which reliably predicted the onset of sepsis nine times out of ten. Combining this gene signature with Reverse Transcription Polymerase Chain Reaction (RT-PCR), the test achieved 94% accuracy in early detection, allowing for quicker intervention.
To bring this technology closer to bedside use, the National Research Council of Canada (NRC) developed PowerBlade, a portable device that uses a tiny blood sample and automated process to detect sepsis swiftly. In trials with 30 patients, PowerBlade demonstrated 92% accuracy in identifying high-risk individuals and 89% in ruling out low-risk patients, providing results in under three hours. This rapid turnaround could revolutionize emergency care and remote healthcare settings.
The interdisciplinary collaboration behind this innovation integrates advances in microfluidics, engineering, and biology, enabling accessible and portable diagnostics. The Sepset testing platform is currently under commercial development, promising to empower clinicians with early warning tools and improve patient outcomes.
These advancements highlight the vital role of artificial intelligence and microfluidic technology in transforming critical care diagnostics and offering hope for reducing sepsis-related mortality worldwide. Source: medicalxpress.com
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Study Finds No Survival Benefit of Concurrent Durvalumab with Chemoradiotherapy in Unresectable Stage III NSCLC
A groundbreaking phase III trial reveals that adding durvalumab concurrently with chemoradiotherapy does not improve overall survival in patients with unresectable stage III NSCLC, reaffirming the current standard of post-CRT consolidation therapy.
Innovative Upper-Limb Therapy Developed by Physical Therapist Mother for Her Son
A pioneering at-home upper-limb therapy program utilizing 3D printing has transformed rehabilitation for children with congenital limb differences, demonstrating significant improvements in functionality and quality of life.
High-Resolution Open Geodata Enhances Targeted Mosquito Control Strategies
Innovative use of openly available geospatial data has led to high-resolution maps that improve targeted mosquito control, aiding efforts against disease-carrying Aedes aegypti in urban environments.
New Insights into Messanger RNA Fragments Offer Hope for Advanced Brain Tumor Immunotherapy
Innovative research from CHOP uncovers how missing microexon fragments in messenger RNA may lead to new targeted immunotherapies for hard-to-treat brain tumors like glioma.